medigraphic.com
Boletín Clínico de la Asociación Médica del Hospital Infantil del Estado de Sonora

2011, Número 1

<< Anterior Siguiente >>

Bol Clin Hosp Infant Edo Son 2011; 28 (1)


Fiebre Prolongada en Enfermedades Autoinmunes en Pediatría. Diagnóstico y Alteraciones Inmunológicas

Arroyave-Hernández CM

Idioma: Español
Referencias bibliográficas: 40
Paginas: 23-26
Archivo PDF: 36.90 Kb.


RESUMEN

El aumento de la temperatura corporal o fiebre, es uno de los síntomas mas frecuentes dentro de la patología pediátrica. Sin embargo, a pesar de nuevas técnicas de laboratorio molecular, hay casos en que el origen es difícil de identificar. Se reporta que 47%de los casos es por una infección, 16% neoplasias, 8% enfermedades del tejido conjuntivo y el resto etiologías varias y hasta en un 14% no se tiene un diagnóstico. Se presentan en este trabajo algunas de las características de la fiebre y alteraciones inmunológicas en fiebre reumática, artritis reumatoide juvenil, lupus eritematoso sistémico, enfermedad mixta del tejido conectivo y en dermatomiositis juvenil.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mackowiak P. Concepts of fever. Arch Inter Med 1998; 158: 1870-81.

  2. Dalal S, Zhokovsky D. Pathophysiology and management of fever. J. Suppor. Onco 2006; 4: 9-16.

  3. Thompson H. Fever: a concept analysis. J Adv Nurs 2005; 51: 484-92.

  4. Benedetti M. Fiebre en la edad pediátrica. Acta Pediatr Lat. 1994; 47: 338-48.

  5. Conrad WL, Voorhis W. Review nomenclature and biologic significance of cytokines involved in inflammation and the host immune response. J Infect Dis 1995; 172: 1573-80.

  6. Lifshitz A. Fever: friend or foe? Arch Med Res 1994; 25: 283-6.

  7. Luheshi G, Rothwell N. Cytokines and fever. Int Arch Allergy Immonol 1996; 109301-7.

  8. Kluger MJ. Historical aspects of fever and its role in disease. En: Cox B, Lomax P. Thermorregulatory mechanisms and their therapeutic implications. Basel: Karger, 1980: 65-70.

  9. Kluger MJ, Kozak W, Conn CA, León LR, Soszynski D. The adaptative value of fever. Infect Dis Clin North Amer 1996; 10: 1-20.

  10. Hiramoto R, Rogers C, Dimissie S, Hsuch CM, Hiramoto M, Lorde J et al. The use of conditioning to probe for CNS pathways that regulate fever and NK cells activity. Int J Neurosci 1996; 84: 229-45.

  11. Nademi Z, Clark J, Richards CG, Walshaw D, Cant AJ. The causes of fever in children attending hospital in the north of England. J Infect 2001; 43: 221-5.

  12. Akpede G, Akenzua G. Management of children with prolonges fever of unknown origin and difficulties in the management offever of unknown origin in children in developing countries. Pediatr Drug 2001; 3: 247.

  13. Hayani A, Mahioney OH, Ferbach DJ. Role of bone marrow examination in the child with prolonged fever. J Pediatr 1990; 16: 19-20.

  14. Steele RW, Jones SM, Lowe BA, et al. Usefulness of scanning procedures for diagnosis of fever of unknown origin in children. J Pediatr 1991; 119: 525-30.

  15. Pasic S, Minic A, Djutric P. Fever of unknown origin in 185 paediatric patients: a single-centr e experience. Acta Paediatr 2006; 95: 463-6.

  16. Cunha B. Fever of unknown origin: clinical overview of classical and current concepts. Infect Dis Clin North America. 2007; 21: 867-915.

  17. Jones TD. Diagnosis of rheumatic fever. Jama 1944; 126: 481-84.

  18. Special report: Jones Criteria (revised) for guidance in the diagnosis of rheumatic fever. Circulation 1984; 69: 204 A.

  19. Chopra P and Gulwani H. Pathology and pathogenesis of rheumatic heart disease. Indian J Pathol Microbiology. 2007; 50: 685-97.

  20. Goldbach-Mansky R. Blocking interleukin-1 in rheumatic diseases. Ann N Y Acad Sci 2009; 1182: 111-23.

  21. Azevedo PM, Bauer R, Caparbo Vde F, Silva CA, Bonfá E and Pereira RM. Interleukin-1 receptor antagonist gene (IL1RN) polymorphism possibly associated to severity of rheumatic carditis in a Brazilian cohort. Cytokine 2010; 49: 109-13.

  22. Cassidy JT, LevinsonJE, Brewer EJ Jr. The development of classification criteria for children with juvenile rheumatoid arthritis. Bull Rheum Dis 1989; 38: 5.

  23. Carreño R y del Rio B. En: Reumatologia pediátrica. Artritis reumatoide Juvenil. México: Interamericana-McGraw Hill 1994 87-111.

  24. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, Grom AA. Arthritis Res Ther 2005; 7: R30-R37.

  25. Mangge H, Kenzian H, Gallisti S, Neuwirth G, Liebmann P, et al. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis & Rheum 1995; 38: 221-20.

  26. Yilmaz M, Kendirli SG, Altintas D et al. Cytokine levels in serum of patients with juvenile rheumatoid arthritis. Cli Rheumatol 2001; 20: 30-6.

  27. Madson KL, Moore TL, Lawrence JM., et al. Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis. J Rheumatology 1994; 21 2359.

  28. Tan EM, Cohen AS, Fries JF, et al The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum., 1982; 25: 1271-7.

  29. Arroyave C M, de la Garza P, Benavides ME. En: Lupus el gran simulador Ed: Cuellar 2000 México p 50-52,70-78.

  30. Anolik JH. B cell biology and dysfunction in SLE. Bull NYU Hosp Jt Dis 2007; 65: 182-6.

  31. Nagy G, Koncz A, Perl A. T and B cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol. 2005; 25: 123-40.

  32. Sharp GC, Irvin WS. Mixed connective tissue disease. An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). AMM J of Med 1972; 52: 148.

  33. Souvert J, Chudwin D, Ware K, col. Clinical and laboratory findings in childhood mixed connective tissue disease. Presence of antibody to ribonucleoprotein contain the small nuclear ribonuclear acid U1. J Pediatr 1983; 63: 92-107.

  34. Bohan A, Peters JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 344-7 y 403-7.

  35. Cassidy JT, Petty RE (eds). Juvenil dermatomyositis. En : Textbook of pediatric rheumatology, New York: Churchill Livingstone, 1990:331-75.

  36. Marie I, Lahaxe L, Benveniste O, Delavigne K, Adoue D, et al. Long-term outcome of patients with polymyositis/dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 2010; 162: 337-44.

  37. Plotz H, Dalakas M, Left R, Love LA, Miller FN, Cronin ME.Current concepts in the idiopathic inflammatory myopathies: polimyositis, dermatomyositis and related disorders. An Intern Med 1989;111: 143-57.

  38. Faure MA, Rodriguez RS, Sienra JL, del Rio B, Gomez MP. Dermatomiositis juvenil: características clínicas, inmunológicas y terapeúticas. Bol Med Hosp Inf Mex 1993.

  39. Jain A, Sharma MC. Sarkar C, Bhatia R, Singh S, Gulati S and Handa R. Detection of the membrane attack complex as a diagnostic tool in dermatomyositis. Acta Neurol Scand 2010:17.

  40. Pachman LM, Maryjowsky MC. Juvenil dermatomyositis and polymyositis. Clin Rheuma Dis 1984;10:95-115.




2020     |     www.medigraphic.com